mutLBSgeneDB |
Gene summary for UBE2D2 |
Gene summary |
Basic gene Info. | Gene symbol | UBE2D2 |
Gene name | ubiquitin-conjugating enzyme E2D 2 | |
Synonyms | E2(17)KB2|PUBC1|UBC4|UBC4/5|UBCH4|UBCH5B | |
Cytomap | UCSC genome browser: 5q31.2 | |
Type of gene | protein-coding | |
RefGenes | NM_003339.2, NM_181838.1, | |
Description | p53-regulated ubiquitin-conjugating enzyme 1ubiquitin carrier protein D2ubiquitin-conjugating enzyme E2 D2ubiquitin-conjugating enzyme E2-17 kDa 2ubiquitin-conjugating enzyme E2D 2 (homologous to yeast UBC4/5)ubiquitin-protein ligase D2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 602962 | |
HGNC : HGNC | ||
Ensembl : ENSG00000131508 | ||
HPRD : 04268 | ||
Vega : OTTHUMG00000163282 | ||
Protein | UniProt: P62837 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_UBE2D2 | |
BioGPS: 7322 | ||
Pathway | NCI Pathway Interaction Database: UBE2D2 | |
KEGG: UBE2D2 | ||
REACTOME: UBE2D2 | ||
Pathway Commons: UBE2D2 | ||
Context | iHOP: UBE2D2 | |
ligand binding site mutation search in PubMed: UBE2D2 | ||
UCL Cancer Institute: UBE2D2 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0000209 | protein polyubiquitination | 15247280 | GO:0016567 | protein ubiquitination | 9990509 | GO:0070936 | protein K48-linked ubiquitination | 20061386 |
Top |
Ligand binding site mutations for UBE2D2 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | W141 | T142A | KIRC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for UBE2D2 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | W141 | T142A | -0.88195824 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for UBE2D2 from PDB |
Top |
Differential gene expression and gene-gene network for UBE2D2 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for UBE2D2 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for UBE2D2 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB02418 | (R,R)-2,3-Butanediol | Small molecule |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of UBE2D2 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | OXL | OXALATE(2-) | 5d1k | A | W141 | OXL | OXALATE(2-) | 5d1l | A | W141 | OXL | OXALATE(2-) | 5d1m | A | W141 |
Top |
Conservation information for LBS of UBE2D2 |
Multiple alignments for P62837 in multiple species |
LBS | AA sequence | # species | Species | K144 | REWTQKYAM | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Caenorhabditis elegans | K144 | REWTRKYAI | 2 | Schizosaccharomyces pombe (strain 972 / ATCC 24843), Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) | K144 | REWTKKYAV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | K144 | REWTRKYAM | 1 | Drosophila melanogaster | W141 | RIAREWTQKYA | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | W141 | ATAREWTKKYA | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | W141 | ELAREWTRKYA | 1 | Drosophila melanogaster | W141 | QLAREWTQKYA | 1 | Caenorhabditis elegans | W141 | LSAREWTRKYA | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | W141 | STAREWTRKYA | 1 | Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) | Y145 | EWTQKYAM | 5 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus, Caenorhabditis elegans | Y145 | EWTRKYAI | 2 | Schizosaccharomyces pombe (strain 972 / ATCC 24843), Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) | Y145 | EWTKKYAV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | Y145 | EWTRKYAM | 1 | Drosophila melanogaster |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |